Sunday, 27 November 2016

Polycystic ovary syndrome: clinical implication in perimenopause

2014 Dec;13(6):348-51. doi: 10.5114/pm.2014.47988. Epub 2014 Dec 30.

  • 1Department of Laboratory Diagnostics, Medical University of Lublin, Poland ; Department of Endocrinology, Medical University of Lublin, Poland.
  • 2Department of Endocrinology, Medical University of Lublin, Poland.
  • 33 Chair and Department of Gynecology, Medical University of Lublin, Poland.
  • 4Department of Laboratory Diagnostics, Medical University of Lublin, Poland.


Polycystic ovary syndrome (PCOS), a hyperandrogenic disorder, is the commonest endocrinopathy in premenopausal women. This syndrome is associated with fertility problems, clinical manifestations of hyperandrogenism and metabolic disturbances, particularly insulin resistance and obesity. There is a great body of evidence that patients with PCOS present multiple cardiovascular risk factors and cluster components of metabolic syndrome from early ages. The presence of comorbidities such as abdominal obesity, insulin resistance, type 2 diabetes, hypertension places these females at an increased risk of future cardiovascular events. However, the extent to which PCOS components are present in perimenopausal women and the degree to which PCOS increases various risk factors in addition to the known risk of the perimenopausal period have not been fully determined. The perimenopausal period per se is associated with weight gain and an increased cardiovascular risk, which may be additionally aggravated by the presence of metabolic disturbances connected with PCOS. The phenotype of PCOS may improve with aging and it is still uncertain whether the presence of PCOS significantly increases the cardiovascular risk later in women's life. Most recent data suggest that the prevalence of cardiovascular diseases and the related long-term consequences in females with PCOS seem to be lower than expected. This manuscript reviews long-term consequences of PCOS and considers their clinical implications in perimenopause.


PCOS; cardiovascular risk; insulin resistance; menopause; perimenopause